Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hidekazu Itamura, M. D. , Takero Shindo, M. D. , Ph. D

Similar presentations


Presentation on theme: "Hidekazu Itamura, M. D. , Takero Shindo, M. D. , Ph. D"— Presentation transcript:

1 The MEK Inhibitor Trametinib Selectively Suppresses GVHD, While Sparing GVT Effects 
Hidekazu Itamura, M.D., Takero Shindo, M.D., Ph.D., Isao Tawara, M.D., Ph.D., Ryusho Kariya, M.S., Seiji Okada, M.D., Ph.D., Krishna V. Komanduri, M.D., Shinya Kimura, M.D., Ph.D.  Biology of Blood and Marrow Transplantation  Volume 21, Issue 2, Pages S333-S334 (February 2015) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 Trametinib suppresses GVHD in the BDF1 model
Biology of Blood and Marrow Transplantation  , S333-S334DOI: ( /j.bbmt ) Copyright © Terms and Conditions

3 Figure 2 Peripheral blood T cells of BDF1-GVHD mice show increased phosphorylation of ERK, which is suppressed by Trametinib Biology of Blood and Marrow Transplantation  , S333-S334DOI: ( /j.bbmt ) Copyright © Terms and Conditions

4 Figure 3 Trametinib spares GVT effects
Biology of Blood and Marrow Transplantation  , S333-S334DOI: ( /j.bbmt ) Copyright © Terms and Conditions


Download ppt "Hidekazu Itamura, M. D. , Takero Shindo, M. D. , Ph. D"

Similar presentations


Ads by Google